4//SEC Filing
Schroeder Thilo 4
Accession 0001209191-22-043221
CIK 0001628171other
Filed
Jul 25, 8:00 PM ET
Accepted
Jul 26, 5:12 PM ET
Size
7.4 KB
Accession
0001209191-22-043221
Insider Transaction Report
Form 4
Schroeder Thilo
Director
Transactions
- Purchase
Common Stock
2022-07-22$20.00/sh+250,000$5,000,000→ 1,221,315 total(indirect: By Nextech Crossover I SCSP)
Holdings
- 2,668,214(indirect: By Nextech V Oncology S.C.S., SICAV-SIF)
Common Stock
- 300,000(indirect: By Nextech VI Oncology SCSp)
Common Stock
Footnotes (3)
- [F1]Nextech Invest AG is the investment advisor of Nextech Crossover I SCSP ("Nextech Crossover"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech Crossover. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
- [F2]Nextech Invest AG is the investment advisor of Nextech V Oncology S.C.S., SICAV-SIF ("Nextech V"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech V. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
- [F3]Nextech Invest AG is the investment advisor of Nextech VI Oncology SCSp ("Nextech VI"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech VI. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
Documents
Issuer
Revolution Medicines, Inc.
CIK 0001628171
Entity typeother
Related Parties
1- filerCIK 0001776412
Filing Metadata
- Form type
- 4
- Filed
- Jul 25, 8:00 PM ET
- Accepted
- Jul 26, 5:12 PM ET
- Size
- 7.4 KB